Genre
- Journal Article
Variation in the formation and disposition of the hydroxylamine of (SMX-HA) is thought to play an important role in the pathogenesis of sulfamethoxazole(SMX)-induced idiosyncratic adverse drug reactions. We hypothesized that, in analogy to carcinogenic arylamines, SMX-HA might be further converted to an electrophilic N-acetoxy metabolite which could play a role in mediating SMX toxicity. Accordingly, we chemically synthesized N-acetoxy-SMX, and examined the characteristics of its formation, metabolism, cytotoxicity and mutagenicity in human and bacterial test systems. The human arylamine N-acetyltransferases, (NAT)1 and NAT2, were capable of converting SMX-HA to N-acetoxy-SMX. NAT1 and NAT2 possessed similar affinities for SMX-HA (apparent K-m values of 650 and 520 mu M, respectively), but the apparent maximal velocity of the NAT1-mediated acetylation was higher than that of NAT2. (1332 vs. 37 nmol/min/U of immunoreactive NAT protein). Human peripheral blood mononuclear cells 12,000 x g supernatant fractions converted N-acetoxy-SMX mainly back to SMX-HA, and also to a lesser extent to SMX, at clinically relevant concentrations. Similar pathways were observed in human hepatic cytosolic fractions. In a cytotoxicity assay, N-acetoxy-SMX was significantly more toxic to human peripheral blood mononuclear cells than SMX-HA (16.6 vs. 11.5% dead cells at a concentration of 300 mu M). N-acetoxy-SMX was weakly mutagenic to the Salmonella typhimurium TA100 strain in the Ames test. These data suggest that the N-acetoxy metabolites of sulfonamides could potentially play a role in mediating sulfonamide idiosyncratic adverse drug reactions.
UNIV TORONTO,FAC PHARM,TORONTO,ON,CANADA. HOSP SICK CHILDREN,DEPT PEDIAT,TORONTO,ON M5G 1X8,CANADA. UNIV GUELPH,DEPT CHEM & BIOCHEM,GUELPH,ON N1G 2W1,CANADA.
BALTIMORE; 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436
WILLIAMS & WILKINS
PT: J; CR: BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248 CRIBB AE, 1990, DRUG METAB DISPOS, V18, P784 CRIBB AE, 1990, VET RES COMMUN, V14, P241 CRIBB AE, 1991, DRUG METAB DISPOS, V19, P900 CRIBB AE, 1991, J PHARMACOL EXP THER, V259, P1241 CRIBB AE, 1991, MOL PHARMACOL, V38, P744 CRIBB AE, 1992, CLIN PHARMACOL THER, V51, P522 CRIBB AE, 1993, BIOCHEM PHARMACOL, V45, P1277 DUPRET JM, 1992, J BIOL CHEM, V267, P7381 FAMULOK M, 1989, ANGEW CHEM INT EDIT, V28, P337 GRANT DM, 1990, J CLIN INVEST, V85, P968 GRANT DM, 1991, MOL PHARMACOL, V39, P184 GRANT DM, 1992, CANCER RES, V52, P1 HANNA PE, 1985, BIOACTIVATION FOREIG, P375 HEIN DW, 1987, CARCINOGENESIS, V8, P1767 HEIN DW, 1993, CARCINOGENESIS, V14, P1633 MCMANUS ME, 1989, CLIN EXP PHARMACOL P, V16, P491 RIEDER MJ, 1987, J PHARMACOL EXP THER, V244, P724 RIEDER MJ, 1989, ANN INTERN MED, V110, P286 RIEDER MJ, 1991, CLIN PHARMACOL THER, V49, P13 RILEY RJ, 1991, BIOCHEM PHARMACOL, V42, P696 SHEAR NH, 1985, CAN J PHYSIOL PHARM, V63, P1370 SHEAR NH, 1986, ANN INTERN MED, V105, P179 SPIELBERG SP, 1980, J PHARMACOL EXP THER, V213, P395 THOMPSON DC, 1992, MUTAT RES, V279, P83; NR: 25; TC: 21; J9: J PHARMACOL EXP THER; PG: 6; GA: RV893
Source type: Electronic(1)
Language
- English
Subjects
- HYDROXYLAMINE METABOLITES
- GLUTATHIONE
- predisposition
- ACTIVATION
- Pharmacology & Pharmacy
- SLOW ACETYLATOR PHENOTYPE
- SULFONAMIDE HYPERSENSITIVITY REACTIONS
- INVITRO
- IDIOSYNCRATIC TOXICITY
- TRANSFERASE
- ACETYLTRANSFERASE